+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
ID07177911

Phase I Trial to Assess Safety, Effectiveness, and Immune Response of CC312 in Adults Aged 18-65 With Moderate to Severe Systemic Lupus Erythematosus

Led by CytoCares Inc · Updated on 2025-09-17

32

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating CC312 in adults with moderate to severe systemic lupus erythematosus SLE in a Phase I randomized, double-blind, placebo-controlled trial. This study aims to assess the safety, tolerability, how the body processes the drug pharmacokinetics, immune response, and early signs of effectiveness of CC312 in patients who have active disease despite standard treatments. Participants will receive either a single intravenous dose of CC312 or placebo. After 21 days, if safety and tolerability are confirmed by investigators and the sponsor, participants may enter a phase of multiple intravenous doses. The study compares CC312 to placebo and carefully monitors responses during these dosing phases. During the trial, participants will be closely observed for adverse events over two years. Researchers will measure drug levels in the blood, immune cell counts, specific lupus-related antibodies, and disease activity scores. Safety assessments include monitoring for serious reactions and immune responses to CC312. This extended follow-up helps understand the drugs impact and participant safety over time.

CONDITIONS

Brief Title

Safety and Efficacy Study of CC312 for Moderate to Severe SLE

Research Team

C

CEO

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here